IL2 and neuroblastoma: Dinutuximab is used in combination with interleukin-2, granulocyte–macrophage colony-stimulating factor, and isotretinoin (13-cis-retinoic acid) for maintenance treatment of pediatric patients with high-risk neuroblastoma who has achieved at least a partial response to first-line multiagent, multimodality therapy32.